Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

The WHO 2007 glioma classification system (based primarily on tumour histology) resulted
in considerable interobserver variability and substantial variation in patient survival within …

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from
the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of …

Diffuse gliomas are the most common malignant brain tumours in adults and include
glioblastomas and World Health Organization (WHO) grade II and grade III tumours …

Tumor-associated macrophages (TAMs) play an important role in the immune response to
cancer, but the mechanisms by which the tumor microenvironment controls TAMs and T cell …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear,. Here we analysed temporally separated DNA-sequencing …

Glioblastoma (GBM) is a highly lethal brain tumor with poor responses to immunotherapies
that have been successful in more immunogenic cancers with less immunosuppressive …

Heterotypic interactions across diverse cell types can enable tumor progression and hold
the potential to expand therapeutic interventions. Here, combined profiling and functional …